mechanism necessary to oppose the increased generation of ROS in failing myocardium, as suggested by the observation that G6PD inhibition in cardiomyocytes compromises antioxidant capacity and increases sensitivity to ROS-induced cell death. 3, 12, 13 G6PD deficient (G6PDX) mice develop normally but are affected with moderate cardiac hypertrophy at 9 months of age. 3 Myocardial ischemia/reperfusion causes greater oxidative stress and injury in G6PDX compared with wild-type (WT) mice. 3, 4 On the other hand, pharmacological inhibition of G6PD decreased ROS generation in myocardial homogenates from failing hearts, suggesting that G6PD fuels NADPH dependent oxidant enzymes in advanced heart failure. 1, 11 Potential benefits of G6PD deficiency have also been reported on the vasculature. 14, 15 However, no studies have addressed the effects of chronic suppression of G6PD on the development and progression of heart failure. 8, 9 The goal of the present investigation was to test the hypothesis that G6PD deficiency would protect against the development of heart failure by decreasing NADPH and ROS production in myocardium subjected to injury or chronic, severe stress. G6PDX mice, which have ≈40% residual G6PD activity and recapitulate key aspects of clinical deficiency, 16 were subjected to myocardial infarction caused by left coronary artery ligation or to transverse aortic constriction (TAC) to induce pressure overload. Alterations in left ventricular (LV) mass, chamber remodeling, ROS production, and lipid peroxidation were assessed. We further fed these mice with a high fructose diet to increase flux through pro-oxidant NADPH dependent enzymes. [17] [18] [19] [20] Recent studies from our laboratory and others have found that high fructose intake exacerbated the development of heart failure and accelerated mortality compared with a complex carbohydrate diet in saltinduced hypertension, 21, 22 TAC, 17, 23 and volume overload 24 models of heart failure. Thus, we further hypothesized that G6PD deficiency would prevent the adverse cardiac effects of high fructose intake in mice subjected to TAC.
Methods

Experimental Design
Infarct Experimental Design
Sixteen week-old male mice underwent permanent coronary occlusion or sham surgery. Cardiac function was assessed by echocardiography at 11 weeks and by intraventricular catheterization during euthanization at 12 weeks after surgery.
TAC Experimental Design
Ten week-old male mice underwent TAC or sham surgery. TAC was performed using a 28-gauge needle. Echocardiography was performed 1 to 2 days before euthanization at 6 weeks after surgery.
Fructose/TAC Experimental Design
Eight week-old male mice underwent sham or TAC surgery with a 27-gauge needle and were fed with a high starch diet or high fructose diet, which consisted of 60% of energy intake from fructose on the next day. Blood pressure was measured by tail cuff plethysmography at 10 weeks after surgery; echocardiography was performed at 16 weeks; and mice were euthanized at 17 weeks for biochemical analysis.
Animal Treatment
Male G6PDX mice were generated previously on a C3H/HeJ background by Pretsch et al. 16 G6PDX and WT littermates were transferred from Dr Leopold's laboratory at Harvard Medical School to the University of Maryland, Baltimore, genotyped as previously described, 4 and used as founders for separate colonies of G6PDX mice and WT mice. Subsequent offspring of the third to fifth generations were used in our experiments. Animals were fed ad libitum and maintained on a 12-hour light/dark cycle. In the first 2 series, mice were fed with a standard laboratory chow, which consisted of 18% of energy from fat, 58% carbohydrate, and 24% protein (2018SX, Teklad Diets, Indianapolis, IN). Animals in the fructose/TAC study were fed custom manufactured purified diets (See Material in the online-only Data Supplement) (Research Diets Inc, New Brunswick, NJ). All procedures were conducted in accordance with the Guidelines for the Care and Use of Laboratory Animals (National Institute of Health publication No. 85-23) and were approved by the University of Maryland Animal Care and Use Committee.
Mouse Surgery
For all surgical procedures, mice were anesthetized with 2% isoflurane in oxygen and ventilated at a tidal volume of 0.30 mL at 80 breaths/min (Harvard Apparatus Inspira, Holliston, MA). Isoflurane was vaporized using a SurgiVet model 100 vaporizer from Atlantic Biomedical (Baltimore, MD).
Myocardial Infarction
Infarction was induced by permanent left anterior descending (LAD) occlusion. Anesthetized mice were placed in a position in which they were lying on their side on a warm heating pad. The ribs were separated, and a tapered 7-0 silk suture was used to tie off the LAD. The ribs and skin were then, each, closed with 6-0 silk. Sham animals were subjected to the same procedure except that the LAD was not occluded. Animals were allowed to recover for 3 to 5 minutes with 100% oxygen immediately after surgery and then placed on a warm heating pad for full recovery.
Transverse Aortic Constriction
Pressure overload was induced by TAC. Anesthetized mice were placed in the supine position on a warm heating pad. A 27-gauge (17 week series) or 28-gauge needle (6 week series) was placed next to the transverse aorta, and a 6-0 silk suture was tied around both the aorta and the needle, and the needle was removed. The muscle and skin were closed separately with 6-0 silk suture. Sham animals were subjected to the same surgical procedure except that the aorta was not constricted. Animals were allowed to recover for 3 to 5 minutes with 100% oxygen immediately after surgery and then placed on a warm heating pad.
Tissue Harvest
Mice were anesthetized with 2.5% isoflurane, and the rib cage was opened. A small 20 to 30 mg piece of the LV free wall was quickly cut free and snap frozen, weighed, and kept at -80°C for later NADPH or glutathione measurement. Another portion was mounted for histological analysis. The remainder of the heart was dissected in ice-cold phosphate buffered saline, weighed, frozen in liquid nitrogen, and later ground to powder. Blood was drawn from the thorax and centrifuged for 15 minutes at 1500g to obtain serum. The liver, right kidney, and epididymal fat pads were weighed, and the tibia length was measured. All samples were stored at -80 o C until subsequent analysis.
Statistical Analysis
Continuous data are presented as mean±SE, and categorical data are presented as percentages. Comparisons between strain and treatment groups were made using a 2-way ANOVA. The Holm-Sidak test for multiple comparisons was used to test for difference among WT/ sham versus WT/infarct (or TAC), WT/sham versus G6PDX/sham, G6PDX/sham versus G6PDX/infarct, and G6PDX/infarct versus WT/infarct. Recovery from surgery was assessed by a χ 2 analysis. Postsurgery survival was estimated using the Kaplan-Meier method, and survival among groups was compared using the log-rank test.
A 2 tailed t test was used to compare the difference in infarct size between WT and G6PDX mice. P<0.05 was considered significant.
See Material in the online-only Data Supplement for additional methods.
Results
Myocardial Infarction
Recovery and Survival After Myocardial Infarction
We assessed the effect of G6PD deficiency on heart failure in response to myocardial infarction. A total of 32 WT and 46 G6PDX mice underwent LAD ligation to produce an infarct, whereas 10 WT and 10 G6PDX mice underwent sham surgery. Postinfarct 24-hour survival was 63% for WT and 61% for G6PDX mice. There was minimal mortality from day 1 to 12 weeks after infarction, with no statistically significant differences among groups ( Figure I in the online-only Data Supplement). We found no significant differences in body mass among strain and treatment groups at the time of surgery or at the end of the study ( Table I in the online-only Data Supplement).
G6PD Deficiency Increases LV Dilation After Myocardial Infarction
G6PD mRNA and G6PD activity were decreased in G6PDX mice compared with WT mice, and infarction increased myocardial G6PD mRNA and G6PD activity in WT mice but not in G6PDX mice ( Figure 1A and 1B). Heart mass was increased by LAD ligation, indicating cardiac hypertrophy in both WT and G6PDX mice ( Figure 1C ). We did not find a statistically significant difference in infarct size between strains (WT: 14.2±1.4% of LV, G6PDX: 16.8±1.2% of LV; P=0.168). Myocardial infarction caused eccentric hypertrophy as seen in the A, B, Myocardial G6PD mRNA expression and enzymatic activity were increased by left anterior descending (LAD) ligation in wild-type (WT) mice, but not in G6PD deficient mice. C, Myocardial infarction increased heart mass. D-F, Myocardial infarction increased LV end diastolic and end systolic volume. LV end diastolic volume was increased further by G6PD deficiency, and myocardial infarction resulted in decreased relative wall thickness in G6PDX mice, indicating that G6PD deficiency increased susceptibility to dilation. G-I, Myocardial infarction decreased ejection fraction indicating systolic dysfunction, and increased myocardial performance index (MPI) and LV end diastolic pressure indicating diastolic dysfunction. These functional parameters were unaffected by G6PD deficiency. Data were obtained using mice at 11 to 12 weeks after LAD ligation or sham surgery. For echocardiography measurements, mice were anesthetized with 1.5% isoflurane. *P<0.05 vs sham; #P<0.05 vs WT; sham n=9 to 10/group, WT infarct n=19, G6PDX infarct n=27 to 28. increase in LV end diastolic volume, in both WT and G6PDX mice. However, LV dilation was significantly greater with G6PD deficiency ( Figure 1D and 1E; Table II in the online-only  Data Supplement) , reflected by a greater LV end diastolic volume in G6PDX mice compared with WT mice. G6PDX mice also displayed a decrease in relative wall thickness in G6PDX mice, further indicating that G6PD deficiency increased susceptibility to LV dilation ( Figure 1F ). This corresponded with an increase in myocyte size and a decrease in capillary density in G6PDX mice (Table) . Myocardial infarction decreased systolic and diastolic function, as indicated by decreased ejection fraction and dP/dt min, and increased myocardial performance index and LV end diastolic pressure ( Figure 1G -1I; Figure II in the online-only Data Supplement). Taken together, G6PD deficiency exacerbated LV dilation but did not accelerate systolic or diastolic dysfunction after myocardial infarction.
Effects of G6PD Deficiency on Biochemical Parameters After Myocardial Infarction
Myocardial NADPH is increased in severe heart failure, 1, 11 and we saw an increase in myocardial NADPH in infarcted G6PDX mice ( Figure 2A ). Although myocardial superoxide production was unaffected by infarction or G6PD deficiency, infarction increased myocardial lipid peroxidation products in G6PDX mice, suggesting increased oxidative stress with G6PD deficiency ( Figure 2B and 2C). Heart failure decreases the capacity for oxidative metabolism in myocardium, as reflected in a decrease in the activities of aconitase, citrate synthase, and medium-chain acyl-CoA dehydrogenase (MCAD). The activities of these enzymes were decreased by myocardial infarction but were unaffected by G6PD deficiency (Figure 2D and 2F).
Heart failure increases myocardial mRNA expression of the fetal genes atrial natriuretic peptide (ANP) and myosin heavy chain (MHC )β, and expression of these genes was increased by infarction but unaffected by G6PD deficiency ( Figure 2G and 2H; Table III in the online-only Data Supplement). Taken together, these results suggest that G6PD deficiency increased oxidative stress but not other indicators of heart failure in response to myocardial infarction.
Transverse Aortic Constriction
Recovery and Survival After TAC In addition to myocardial infarction, we assessed the effect of G6PD deficiency on heart failure in response to pressure overload. A total of 28 WT mice and 24 G6PDX mice underwent TAC with a 28-gauge needle to produce severe pressure overload, whereas 7 WT mice and 7 G6PDX mice underwent sham surgery. TAC 24-hour survival was 39% for WT mice and 54% for G6PDX mice (P=0.43 for difference). Minimal mortality was again observed from day 1 to 6 weeks after TAC, with no significant differences among groups ( Figure III in the online-only Data Supplement). There were no statistically significant differences in body mass among strain and treatment groups ( Table IV in the online-only Data Supplement).
G6PD Deficiency Increases the Propensity for LV Dilation After TAC
TAC increased LV mass to the same extent in WT and G6PDX mice ( Figure 3C ). However, only G6PDX mice had a statistically significant increase in LV end diastolic and end systolic volumes, and absolute wall thickness ( Figure 3D -3F; that G6PD deficiency increased the propensity for LV dilation. TAC resulted in decreased systolic function, as indicated by a decrease in ejection fraction, but these parameters were unaffected by G6PD deficiency ( Figure 3G ). TAC increased G6PD mRNA and G6PD activity in WT mice but not in G6PDX mice ( Figure 3A and 3B) .
Effects of G6PD Deficiency on Biochemical Parameters After TAC
As with Myocardial infarction, NADPH was increased in G6PDX mice in response to TAC ( Figure 4A ). G6PD deficiency decreased superoxide production, but this did not prevent a decrease in reduced glutathione (GSH) in response to TAC in G6PDX mice ( Figure 4B and 4C ). There was no effect of G6PD deficiency or TAC on lipid peroxidation products (Figure 4D) . TAC decreased myocardial aconitase activity, citrate synthase activity, and MCAD activity to the same extent in G6PDX and WT mice ( Figure 4E-4G 
High Fructose Intake and Transverse Aortic Constriction
Recovery and Survival After Fructose/TAC
We assessed the effect of G6PD deficiency on heart failure in response to pressure overload with the additional stress of high fructose intake. A total of 55 WT mice and 47 G6PDX mice underwent moderate TAC with a 27-gauge needle, whereas 28 WT mice and 29 G6PDX mice underwent sham surgery.
Immediately after surgery, mice were assigned to either a high starch or a high fructose diet ( Table VII in the onlineonly Data Supplement). TAC 24-hour survival was 65% for WT mice and 72% for G6PDX mice (P=0.594). There was minimal mortality from day 1 to 17 weeks after TAC, with no significant differences among groups ( Figure IV in the onlineonly Data Supplement). There were no statistically significant differences among strain and treatment groups in body mass ( Table VIII in 
G6PD Deficiency Exacerbates the Cardiac Effects of Pressure Overload With High Fructose Intake
TAC increased LV mass in all groups but to a greater extent in G6PDX mice compared with WT mice after high fructose intake ( Figure 5B ). Atrial and right ventricular mass were also increased by TAC, with a greater increase in right ventricular mass in G6PDX mice compared with WT mice after high fructose intake (Table IX in the online-only Data Supplement). TAC resulted in decreased stroke volume and concentric hypertrophy indicated by increased absolute and relative wall thickness (Table X in the online-only Data Supplement). G6PD deficient animals displayed systolic dysfunction, as seen by an increase in LV end systolic volume and a decrease in ejection fraction in response to TAC after high fructose intake ( Figure 5C ). TAC increased LV fetal gene expression, as indicated by increased MHCβ/MHCα and ANP mRNA in all groups ( Figure 5D ; Table XI in the online-only Data Supplement). The greatest ANP expression was in G6PDX mice with the high fructose diet. A, B , TAC increased G6PD mRNA and G6PD activity in (wild-type) WT mice, but not in G6PDX mice. C, TAC increased LV mass to the same extent in WT and G6PDX mice. D-F, TAC increased LV end diastolic volume, end systolic volume, and absolute wall thickness in G6PDX mice. G, TAC decreased systolic function to the same extent in G6PDX and WT mice. Data were obtained using mice at 6 weeks after sham or TAC surgery with a 28-gauge needle. For echocardiography measurements, mice were anesthetized with 1% isoflurane.*P<0.05 vs sham; #P<0.05 vs WT; sham n=7/group, TAC=10 to 12/group.
TAC also increased LV G6PD activity in WT mice on the high starch diet ( Figure 5A ). G6PD activity was unaffected by TAC in WT mice fed with high fructose diet and decreased in G6PDX mice. Taken together, the results indicate G6PD deficiency exacerbates cardiac hypertrophy and dysfunction in response to pressure overload after high fructose intake.
Effects of G6PD Deficiency on Metabolic Parameters After High Fructose Intake and TAC
We hypothesized that a combination of pressure overload and high fructose increases flux through G6PD in WT mice to increase NADPH, superoxide production, and oxidative stress. In accordance with this hypothesis, NADPH was increased in response to TAC in WT mice with high fructose intake ( Figure 6A ). However, contrary to our hypothesis, this increase in NADPH did not correspond with increases in superoxide production or lipid peroxidation ( Figure 6B ; Table  XI in the online-only Data Supplement). On the other hand, decreased aconitase activity is indicative of oxidative stress, 25 and aconitase activity was decreased in response to TAC in G6PDX mice after high fructose intake ( Figure 6C ). These Figure 5 . Glucose 6-phosphate dehydrogenase (G6PD) deficiency exacerbates the cardiac effects of pressure overload with high fructose intake. A, Left ventricular (LV) G6PD activity was increased by transverse aortic constriction (TAC) in the high starch diet and was decreased in G6PDX mice. B, LV mass was increased by TAC in all groups and was increased to the greatest extent in G6PDX mice with high fructose intake. C, Ejection fraction was decreased in G6PDX mice with the high fructose diet. D, LV atrial natriuretic peptide (ANP) mRNA expression was increased by TAC to the greatest extent in G6PD deficient animals with high fructose intake. Data were obtained 16 to 17 weeks post-TAC. For echocardiography measurements, mice were anesthetized with 2.5% isoflurane.*P<0.05 vs TAC; #P<0.05 vs wild-type (WT); sham n=9 to 16/group, TAC n=12 to 16/group.
results suggest that G6PD deficiency may increase rather than decrease oxidative stress in response to high fructose intake and TAC. High sugar intake is associated with increased circulating triglycerides, and adverse metabolic effects may interact with pressure overload to adversely affect heart failure. 26 G6PDX mice had increased serum triglycerides after high sugar intake, indicating that G6PD deficiency increases propensity for hypertriglceridemia ( Figure 6D ). G6PD deficiency also decreased serum insulin in animals with high fructose intake, consistent with a decrease in β-cell function as reported by others ( Table  XII in the online-only Data Supplement). 27 Serum glucose and free fatty acids were unaffected by G6PD deficiency or TAC.
Discussion
The main novel finding of this study is that the progression of heart failure was modestly accelerated by a clinically relevant level of G6PD deficiency. In response to myocardial infarction or chronic pressure overload, G6PDX mice displayed modest but significantly worsening of LV dilation and contractile dysfunction, associated with decreased GSH or increased lipid peroxidation products in cardiac tissue. Thus, contrary to our hypothesis, G6PD deficiency did not attenuate development of myocardial dysfunction and ventricular remodeling in response to injury or pressure overload.
Our hypothesis was based on the observation that pharmacological inhibition of G6PD decreases ROS generation in myocardial homogenates from canine and human failing hearts, suggesting that G6PD fuels NADPH dependent oxidant enzymes in advanced heart failure. 1, 11 On the other hand, given the critical role attributed to the oxidative pentose phosphate pathway in the maintenance of redox homeostasis, one may argue that an alternative hypothesis could have been that G6PD deficiency will exacerbate myocardial pathology in response to chronic stress. This is suggested by the observation that inhibition of G6PD increases the sensitivity of cells to oxidative damage and death, whereas G6PD overexpression protects cells against oxidative damage. 13 Further, the activity of G6PD is enhanced in isolated cardiomyocytes in response to oxidative stress, and inhibition of G6PD increased oxidative stress and impaired cardiomyocyte calcium handling and contractility. 3 In the light of this alternative hypothesis, our observation of a relatively modest effect of G6PD deficiency on LV remodeling and contractile function, and a lack of effect on survival, suggests that G6PD deficiency does not trigger catastrophe in heart failure. Although LV dilation was enhanced in response to G6PD deficiency, accelerated contractile dysfunction was not evident. There may be a complex and evolving balance between negative and positive effects of G6PD deficiency during the progression of heart failure. Previous studies found that G6PDX mice display worse contractile recovery after an acute bout of myocardial ischemia that seemed to be mediated by accelerated oxidative stress. 4 Nonetheless, there might be a transient detrimental consequence of G6PD deficiency in acute stress that is not sufficient to affect long-term outcome.
We expected G6PD deficiency to decrease NADPH concentration, as seen by others in the kidneys of G6PDX mice and in cardiomyocytes with pharmacological inhibition of G6PD. 12, 28 The myocardial concentration of NADPH reflects the NADPH set point, rather than the rate of NADPH production. Further, the G6PD enzymatic activity is an index of the maximal capacity for the reaction, rather than the actual flux through G6PD, which is dependent on cellular location and the concentrations of substrates and products. However, we found that NADPH levels were not significantly different in G6PDX compared with WT mice, and we were surprised to find a significant increase in NADPH concentration in response to either myocardial infarction or TAC in G6PDX. The reason for the increase is unclear but suggests that there are compensatory mechanisms for increasing NADPH. 29 High fructose intake may accelerate heart failure by increasing superoxide production. 17 In the liver, fructose bypasses key regulatory step of glycolysis and causes a transient increase in circulating triglycerides, which could inhibit glycolysis in the heart and increase myocardial glucose flux through nonoxidative pathways such as the pentose phosphate pathway to increase NADPH dependant ROS production. 1, 30, 31 High glucose increased NADPH concentration, NADPH oxidase activity, and ROS, and the glucose-induced increase in Figure 6 . Fructose/Transverse aortic constriction (TAC)-biochemical and metabolic data. A, TAC increased left ventricular (LV) levels of reduced nicotinamide adenine dinucleotide phosphate (NADPH) after high fructose intake in wild-type (WT) mice, but not in glucose 6-phosphate dehydrogenase-deficient (G6PDX) mice. B, Superoxide production was unchanged by TAC or G6PD deficiency among animals that received the high fructose diet or the high starch diet. C, Aconitase activity, an index of oxidative stress, was decreased by TAC in G6PDX mice after high fructose intake. D, G6PD deficiency increased serum triglycerides compared with WT mice with high fructose intake. Data were obtained 17 weeks post-TAC. *P<0.05 vs TAC; #P<0.05 vs WT; sham n=9 to 16/group, TAC n=12 to 16/group. ROS was prevented by G6PD knockdown in cultured adipose cells, 20 and a high fructose diet previously accelerated heart failure via increased ROS. 17 Thus, we hypothesized that high fructose intake would exacerbate heart failure by increasing flux through G6PD to increase NADPH and superoxide production and predicted that G6PD deficiency would have a beneficial effect on the heart in the context of a high fructose diet. We saw an increase in NADPH in WT mice with TAC and high fructose, but not in G6PDX mice, supporting the hypothesis that high sugar intake affects flux through the pentose phosphate pathway. However, this increase in NADPH concentration in WT mice did not correspond to any changes in superoxide production, and G6PD deficiency was not beneficial. Rather, G6PD deficiency resulted in increased triglycerides, and a decrease in aconitase activity, a marker of oxidative stress, which corresponded with greater LV hypertrophy and dysfunction with TAC and high fructose intake. Our results are similar to those seen by Zhang et al 32 , who reported that high glucose decreased G6PD activity and increased oxidative stress in cultured endothelial cells. Our results also support recent findings that pharmacological activation of G6PD suppresses heart failure after myocardial infarction and diabetes mellitus. 33 Thus, G6PD deficiency made the myocardium susceptible to adverse effects of high sugar intake in heart failure.
Study Limitations
The underlying signaling pathways responsible for the increased hypertrophy seen in G6PDX myocardium after TAC with high fructose intake are unclear. Potential pathways include changes in advanced glycation end products, neurohormonal responses, vascular endothelial growth factor, Pim-1, and Akt, as seen by others with pharmacological modulation of the pentose phosphate pathway. 33 Further, it is unclear what effect the increase in NADPH has on NADPH oxidases. These potential mechanisms were not investigated in the present investigation, and this should be addressed in future work. A further limitation to our approach is the use of severe and abrupt pressure overload and coronary ligation in young healthy mice. This differs greatly from clinical heart failure, which generally occurs with advanced age and takes years to develop. Our models might not adequately recapitulate the redox and metabolic conditions in human myocardium that would warrant rescue by G6PD deficiency. This limitation further points toward the importance of human studies to provide clear answers regarding the effects of G6PD deficiency on heart failure.
Conclusion
In summary, we assessed the impact of G6PD deficiency on the development of heart failure using an established genetic mouse model with G6PD deficiency combined with pressure overload or infarct-induced failure. Cardiac dysfunction and LV remodeling was modestly worse with G6PD deficiency, which was associated with greater redox stress. These findings suggest that the risk for developing heart failure is higher, but still limited by compensatory mechanisms, when hypertension or myocardial infarction occur in individuals with G6PD deficiency. Given that G6PD deficiency is the most common deficient enzyme in the world, our findings suggest that further investigation in humans is warranted.
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